HMG CoA reductas
CHRONOPHARMACOTHERAPEUTIC RELEASE OF HMG COA REDUCTASE INHIBITOR: USING NOVEL COATING TECHNIQUE
... words, it is required that the drug should not be released at all during the initial phase of dosage form administration. Such a release pattern is known as pulsatile release. [2] There are many conditions that demand ...
14
56. Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (ex vivo) by medicinal plants from western ghats
... of HMG-CoA reductase (vital enzyme in cholesterol biosynthesis) as the drugs (statins), used in the management of hypercholesterolemia, are associated with side ...inhibit HMG-CoA reductase ...
6
Insilico predictions of inhibitors of novel statin structural analogues with HMG CoA reductase
... Thus HMG-CoA reductase is identified as the initial rate determining factor in cholesterol biosynthesis thus considered as a target widely accepted for drug development studies of cardiovascular disease ...
9
Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening
... atherosclerosis. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase is the key enzyme in the cholesterol biosynthesis pathway, and the statin-like drugs are inhibitors of human HMG-CoA ...
12
An improved industrial process for synthesis of HMG-CoA reductase inhibitor Pitavastatin
... way. HMG-CoA reductase inhibitors are better antagonists for blocking the biosynthesis pathway of ...(or HMG-CoA reductase inhibitors) form a class of hypolipidemic agents, used as ...
6
HMG CoA reductase inhibitor mobilizes bone marrow–derived endothelial progenitor cells
... Endothelial progenitor cells (EPCs) have been isolated from circulating mononuclear cells in peripheral blood and shown to incorporate into foci of neovascularization, consistent with post- natal vasculogenesis. These ...
8
7 Dehydrocholesterol–dependent proteolysis of HMG CoA reductase suppresses sterol biosynthesis in a mouse model of Smith Lemli Opitz/RSH syndrome
... Thus, the 7DHC that accumulates in patients with SLOS accelerates proteolysis of HMG-CoA reductase enzyme protein, thereby depriving the developing organ- ism of needed sterols. Although this effect might ...
12
3-HMG-CoA Reductase Inhibitors and Inflammation: Underlying Mechanisms and Role in Atherosclerosis
... The 3-HMG-CoA reductase inhibitors, referred to as statins, are one of the most potent lipid lowering drugs. They significantly reduce incidence of cardiovascular mortality and morbidity. Data from clinical ...
7
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
... Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative ...
10
Aplexone targets the HMG CoA reductase pathway and differentially regulates arteriovenous angiogenesis
... 3-hydroxy-3-methylglutaryl- CoA synthase; HMGCR, HMG CoA reductase; FDPS, farnesyl diphosphate synthetase; Cyp51, lanosterol 14 -demethylase; SC4MOL, sterol-C4- methyl oxidase-like; DHCR7, ...
9
Synthesis of HMG-CoA Reductase Inhibitor Lanost-8-en-3β-ol-7, 11-dione through Oxidation of 3β-acetoxylanost-8-en-7, 11-dione with Pyridinium Chlorochromate
... Allylic oxidation of 3B-acetoxylanost-8-ene was accomplished with pyridinium chlorochromate (PCC) and chromium trioxide/ acetic acid to form 3B- acetoxylanost-8-en-7,11-dione, which was later reduced to ...
8
HMG-CoA reductase inhibitor lovastatin upregulates plasminogen activator production through RhoA-signaling in peritoneal cell line Met5A
... synthetic HMG-CoA reductase inhibitors that are potent suppressors of cholesterol biosynthesis in ...of HMG-CoA reductase, statins block the reduction of HMG-CoA to mevalonate ...
5
Towards Application of Bioactive Natural Products Containing Isoprenoids for the Regulation of HMG CoA Reductase—A Review
... isoprenoids. HMG-CoA reduc- tase is a rate-determining enzyme in mevalonate pathway, producing intermediates such as farnesyl and geranylgeranyl pyrophosphates, which lead to by-products such as ...of ...
11
Pleiotropic effects of the HMG-CoA reductase inhibitors
... Abstract: The HMG-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia. They have also demonstrated a benefit in a variety of other disease processes. These secondary ...
11
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
... specifically HMG-CoA reductase inhibitors, has been reported to have immunosuppressive effects in a study of heart transplant recipients ...of HMG-CoA reductase inhibitor, mostly used as ...
5
Statins and Sepsis: Possible Connections and Therapeutic Implications
... mortality continues to increase. A delicate balance exists between widespread triggering of defence mechanism by invading micro-organisms and both direct/indirect effects of the micro-organisms and their products. It has ...
5
INHIBITION OF 3 HYDROXY 3 METHYLGLUTARYL COENZYME A (HMG Co A) REDUCTASE IN LIVER MICROSOMES BY MORINGA OLEIFERA L POLYPHENOLS
... With increased interest in dietary phenolic compounds in cereals, herbs, fruits, roots and vegetables as protective agents against coronary heart disease and cancer 3, 6, 28 , results obtained in the present ...
7
Unexpected inhibition of cholesterol 7 alpha hydroxylase by cholesterol in New Zealand white and Watanabe heritable hyperlipidemic rabbits
... hydroxylase and hepatic LDL receptor function and mRNA levels in 23 New Zealand White (NZW) and 17 Watanabe heritable hyperlipidemic (WHHL) rabbits. Plasma cholesterol concentrations were 9.9 times greater in WHHL than ...
9
Journal of Applied Pharmaceutical Science
... longer trial may also help answer whether the trends seen in a shorter trial is actually realized. That is, if TNOB trend for lowering cholesterol levels after just one month of use continues to lower cholesterol levels ...
6
Evaluation of Food Effects on the Oral Pharmacokinetics of Rosuvastatin
... Statin medications are first-line pharmacotherapy for the treatment of hypercholesterolemia and prevention of cardiovascular disease, and an estimated 25.2 million Americans are currently receiving statin therapy ...
102